The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC)
Phase of Trial: Phase II
Latest Information Update: 07 Apr 2017
At a glance
- Drugs Ranolazine (Primary)
- Indications Cardiomyopathies; Coronary artery disease; Left ventricular dysfunction
- Focus Proof of concept; Therapeutic Use
- Acronyms ERIC
- Sponsors Gilead Sciences
- 05 Apr 2017 Status changed from recruiting to discontinued.
- 26 Jan 2016 Planned End Date changed from 1 Dec 2014 to 1 Dec 2016 as reported by ClinicalTrials.gov.
- 26 Jan 2016 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2016 as reported by ClinicalTrials.gov.